Skandinaviska Enskilda Banken AB publ Has $5.76 Million Stock Holdings in AstraZeneca PLC $AZN

Skandinaviska Enskilda Banken AB publ lowered its stake in AstraZeneca PLC (NASDAQ:AZN) by 3.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 82,473 shares of the company’s stock after selling 2,928 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in AstraZeneca were worth $5,762,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in AZN. Norges Bank bought a new stake in AstraZeneca in the second quarter valued at about $4,219,000. Scotia Capital Inc. boosted its holdings in AstraZeneca by 36.2% during the second quarter. Scotia Capital Inc. now owns 413,285 shares of the company’s stock worth $28,880,000 after buying an additional 109,800 shares during the last quarter. Level Four Advisory Services LLC grew its position in shares of AstraZeneca by 17.3% during the 2nd quarter. Level Four Advisory Services LLC now owns 25,718 shares of the company’s stock worth $1,797,000 after buying an additional 3,789 shares during the period. Quadrant Capital Group LLC grew its position in shares of AstraZeneca by 1.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 93,222 shares of the company’s stock worth $6,514,000 after buying an additional 1,397 shares during the period. Finally, Thornburg Investment Management Inc. increased its stake in shares of AstraZeneca by 3.6% in the 2nd quarter. Thornburg Investment Management Inc. now owns 535,650 shares of the company’s stock valued at $37,431,000 after acquiring an additional 18,563 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Down 0.8%

Shares of AZN stock opened at $92.60 on Monday. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $94.01. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The firm has a fifty day moving average of $84.55 and a 200-day moving average of $77.77. The company has a market capitalization of $287.19 billion, a price-to-earnings ratio of 34.81, a P/E/G ratio of 1.52 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.14 by $0.05. The business had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm’s revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.08 EPS. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AZN. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.